ReviewCNS drugs2026
The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.
Review in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cenobamate is a novel alkyl-carbamate antiseizure medication (ASM) that represents a major breakthrough in the treatment of drug-resistant epilepsy, particularly focal seizures. Unlike other ASMs, cenobamate achieves seizure freedom in up to one third of patients with focal drug-resistant epilepsy-a response not observed with other therapies. Herein, we describe the chemocentric and phenotypic screening strategy employed by one of us (Yong Moon Choi) while at SK Biopharmaceuticals and how cenobamate was developed by optimizing earlier alkyl-carbamates such as carisbamate and felbamate. We discuss how the incorporation of a tetrazole moiety likely played a significant role in its successful development. Cenobamate was found to display potent broad-spectrum activity in diverse disease-relevant rodent models, including maximal electroshock, pentylenetetrazole, kindling, and lithium-pilocarpine-induced status epilepticus. When compared to 12 other ASMs, it ranked highest across four models of difficult-to-treat focal seizures. We discuss how the two known molecular activities of cenobamate, i.e., positive allosteric modulation of GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.